Issue Archive

In this issue of Blood, Aljabri and colleagues report on their analysis of the cost-effectiveness of fondaparinux for the treatment of heparin-induced thrombocytopenia (HIT) in the United States.¹  HIT is a relatively uncommon but serious complication of the use of heparin-containing products.²  Treatment of HIT requires use of an alternate anticoagulant such as the direct thrombin inhibitors argatroban and bivalirudin.³ 

In this issue of Blood, Bocchini et al report a novel mechanism by which STAT3 mutations result in an unstable protein and give rise to a reduction in STAT3 signaling, suggesting that pathogenic mutations do not always confer dominant-negative effects via forming of nonfunctional STAT3 dimers but some may limit availability of total protein causing STAT3 haploinsufficiency.¹ 

In this issue of Blood, Xu-Monette et al show that CD37 protein expression is a strong prognostic marker in diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP.¹  CD37 negativity is associated with poor outcome and a high prevalence of adverse genetic and biologic features.¹ 

In this issue of Blood, Bottoni et al demonstrate that histone deacetylase (HDAC) inhibition promotes the upregulation of microRNAs (miRNAs or miRs) which target Bruton tyrosine kinase (BTK), subsequently suppressing prosurvival signaling in chronic lymphocytic leukemia (CLL) samples, and highlight a rationale for HDAC inhibitors in combination with ibrutinib to treat patients.¹ 

A unique feature of megakaryocyte maturation is the switch from mitosis to replication of DNA without cell division, a process termed endomitosis. In this issue of Blood, Roy et al elegantly demonstrate that RhoA/ROCK signaling is critical for the differential activity and localization of nonmuscle myosin (NM) IIA and IIB isoforms at the megakaryocyte cleavage furrow, a key step in the induction of endomitosis.¹ 

In this issue of Blood, Liu et al investigated the mechanism of action in antibody-mediated immune suppression (AMIS) and the fate of antigen in a KEL mouse model system.¹ 

Publisher's Note: There is an Inside Blood Commentary on this article in this issue.

Publisher's Note: There is an Inside Blood Commentary on this article in this issue.

Publisher's Note: There is an Inside Blood Commentary on this article in this issue.

Publisher's Note: There is an Inside Blood Commentary on this article in this issue.